PROM1 and cancer: Many inmunotherapeutic strategies can be used to target OCSCs, and some of them have already been researched in some works: NK cell, cancer therapeutic vaccine (a CD177/CD44 vaccine), monoclonal antibody immunotherapy (catumaxomab, which can bind to CD133 and EpCAM) and the blockade of immune checkpoints.